In vivo and in vitro analyses of the effects of a novel high-nitrogen low-nickel coronary stent on reducing in-stent restenosis

Abstract

Currently, percutaneous coronary intervention is an important treatment for coronary heart disease. However, the in-stent restenosis rate is still approximately 10–30% after stenting. Nickel ions from the stent are considered to be associated with in-stent restenosis. Therefore, in the present study, we quantitatively evaluated in-stent restenosis after implanting the novel high-nitrogen low-nickel coronary stent (HNS) and studied the mechanism underlying the reduction in in-stent restenosis by using ELISA and Western blot. The in vivo results showed that the HNS could significantly reduce neointima formation and inflammation as compared to SUS316L stents (316L) at 180 days after implantation in porcine coronary arteries and that vascular endothelial growth factor-A expression in porcine coronary arteries after HNS implantation also decreased. The in vitro results showed that, in the case of the HNS, human umbilical vein endothelial cell (HUVEC) proliferation was lower and lesser IL-6 release was noted from HUVECs at one and three days after culture than in the 316L group. Furthermore, p-STAT3 expression in HUVECs on the HNS surface was downregulated after culture for seven days. Thus, we conclude that the HNS could be a promising alternative coronary stent for percutaneous coronary intervention.

Keywords

Stent coronary restenosis inflammatory cytokines neointima formation low nickel

Get full access to this article

View all access options for this article.

References

Serruys

Unger

Sousa

et al . Comparison of coronary-artery bypass surgery and stenting for the treatment of multivessel disease. N Engl J Med 2001; 344: 1117–1124.

Garg

Serruys

PW.

Coronary stents: current status. J Am Coll Cardiol 2010; 56: 7.

Kirtane

Gupta

Iyengar

et al . Safety and efficacy of drug-eluting and bare metal stents: comprehensive meta-analysis of randomized trials and observational studies. Circulation 2009; 119: 3198–3206.

Mani

Feldman

Patel

et al . Coronary stents: a materials perspective. Biomaterials 2007; 28: 1689–1710.

Costa

Yan

Zhao

et al . Molecular mechanisms of nickel carcinogenesis: gene silencing by nickel delivery to the nucleus and gene activation/inactivation by nickel-induced cell signaling. J Environ Monit 2003; 5: 222–223.

Koster

Vieluf

Kiehn

et al . Nickel and molybdenum contact allergies in patients with coronary in-stent restenosis. Lancet 2000; 356: 1895–1897.

Saito

Hokimoto

Oshima

et al . Metal allergic reaction in chronic refractory in-stent restenosis. Cardiovasc Revasc Med 2009; 10: 17–22.

Coogan

Latta

Snow

et al . Toxicity and carcinogenicity of nickel compounds. Crit Rev Toxicol 1989; 19: 341–384.

Wataha

Ratanasathien

Hanks

et al . In vitro IL-1 beta and TNF-alpha release from THP-1 monocytes in response to metal ions. Dent Mater 1996; 12: 322–327.

10.

Wataha

Lewis

Volkmann

et al . Sublethal concentrations of Au (III), Pd (II), and Ni(II) differentially alter inflammatory cytokine secretion from activated monocytes. J Biomed Mater Res B Appl Biomater 2004; 69: 11–17.

11.

Asahara

Bauters

Pastore

et al . Local delivery of vascular endothelial growth factor accelerates reendothelialization and attenuates intimal hyperplasia in balloon-injured rat carotid artery. Circulation 1995; 91: 2793–2801.

12.

Stone

Teirstein

Meredith

et al . A prospective, randomized evaluation of a novel everolimus-eluting coronary stent: the PLATINUM (a Prospective, Randomized, Multicenter Trial to Assess an Everolimus-Eluting Coronary Stent System [PROMUS Element] for the Treatment of Up to Two de Novo Coronary Artery Lesions) trial. J Am Coll Cardiol 2011; 57: 1700–1708.

13.

Zhang

Chen

Zheng

et al . A novel high nitrogen nickel-free coronary stents system: evaluation in a porcine model. Biomed Environ Sci 2014; 27: 289–294.

14.

Cilingiroglu

Elliott

Patel

et al . Long-term effects of novel biolimus eluting DEVAX AXXESS plus nitinol self-expanding stent in a porcine coronary model. Cathet Cardiovasc Intervent 2006; 68: 271–279.

15.

Zhao

Liu

et al . Diurnal expression of the Per2 gene and protein in the lateral habenular nucleus. IJMS 2015; 16: 16740–16749.

16.

Zong

Huang

Chen

et al . Downregulation of endogenous hydrogen sulfide pathway is involved in mitochondrion-related endothelial cell apoptosis induced by high salt. Oxid Med Cell Longev 2015; 2015: 754670–754611.

17.

Kastrati

Mehilli

Pache

et al . Analysis of 14 trials comparing sirolimus-eluting stents with bare-metal stents. N Engl J Med 2007; 356: 1030–1039.

18.

Taguchi

Abe

Kanaya

et al . The late-phase inflammatory response after drug-eluting stent implantation. Heart Vessels 2014; 29: 213–219.

19.

Denkhaus

Salnikow

Nickel essentiality, toxicity, and carcinogenicity. Crit Rev Oncol Hematol 2002; 42: 35–56.

20.

Pan

Zhou

et al . Reduction of in-stent restenosis risk on nickel-free stainless steel by regulating cell apoptosis and cell cycle. PLoS One 2013; 8: e62193.

21.

Kaipainen

Korhonen

Mustonen

et al . Expression of the FMS-like tyrosine kinase 4 gene becomes restricted to lymphatic endothelium during development. Proc Natl Acad Sci U S A 1995; 92: 3566–3570.

22.

Katsaros

Kastl

Krychtiuk

et al . An increase of VEGF plasma levels is associated with restenosis of drug-eluting stents. EuroIntervention 2014; 10: 224–230.

23.

Kazmierczak

Grajek

Kowal

et al . Prognostic usefulness of IL-6 and VEGF for the occurrence of changes in coronary arteries of patients with stable angina and implanted stents. Eur Rev Med Pharmacol Sci 2014; 18: 2169–2175.

24.

Huang

Yang

Jiang

et al . Effects of IL-6 and AG490 on regulation of Stat3 signaling pathway and invasion of human pancreatic cancer cells in vitro. J Exp Clin Cancer Res 2010; 29: 51.

25.

Wei

Chou

Chen

et al . The role of IL-6 trans-signaling in vascular leakage: implications for ovarian hyperstimulation syndrome in a murine model. J Clin Endocrinol Metab 2013; 98: 472–484.